The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo in stomach and esophageal cancers based on PD-L1 expression levels—but the ...

We recently published a list of 10 Most Undervalued High Quality Stocks to Buy According to Analysts. In this article, we are ...

Sign Up For Free » Here's a closer look at three discounted S&P 500 dividend stocks you can feel good about buying and ...

Vaccinex, Inc. (OTC: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative ...

2/26，在上市十多年后，Keytruda（帕博利珠单抗）继续实现卓越的年增长，但默沙东（Merck & Co.）认为其黄金时期即将结束，而这一结束的时刻比该产品专利到期时间还要提前几个月。 在本周的一份美国证券文件中，默沙东承认，其癌症免疫疗法重磅药物可能会在明年被美国政府选中进行“定价谈判”，根据《通货膨胀削减法案》（IRA）。默沙东预计，经过谈判的价格将于2028年1月1日起生效，此后“Ke ...

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

A study on mice with melanoma found that aspirin lowered TXA2 levels, which freed up T cells and allowed them to fight cancer more effectively. However, the lead scientist stressed that long-term ...